AU2007322075B2 - Methods of enhancing immune response using electroporation-assisted vaccination and boosting - Google Patents
Methods of enhancing immune response using electroporation-assisted vaccination and boosting Download PDFInfo
- Publication number
- AU2007322075B2 AU2007322075B2 AU2007322075A AU2007322075A AU2007322075B2 AU 2007322075 B2 AU2007322075 B2 AU 2007322075B2 AU 2007322075 A AU2007322075 A AU 2007322075A AU 2007322075 A AU2007322075 A AU 2007322075A AU 2007322075 B2 AU2007322075 B2 AU 2007322075B2
- Authority
- AU
- Australia
- Prior art keywords
- tissue
- muscle
- skin
- electroporation
- boosting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 32
- 230000028993 immune response Effects 0.000 title claims abstract description 27
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 7
- 238000004520 electroporation Methods 0.000 title abstract description 41
- 238000002255 vaccination Methods 0.000 title abstract description 16
- 210000001519 tissue Anatomy 0.000 claims abstract description 64
- 210000003205 muscle Anatomy 0.000 claims abstract description 50
- 229960005486 vaccine Drugs 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 239000000427 antigen Substances 0.000 claims description 28
- 102000036639 antigens Human genes 0.000 claims description 28
- 108091007433 antigens Proteins 0.000 claims description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 241000124008 Mammalia Species 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 230000002500 effect on skin Effects 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 210000003699 striated muscle Anatomy 0.000 claims 1
- 230000037452 priming Effects 0.000 abstract description 26
- 230000000890 antigenic effect Effects 0.000 abstract description 14
- 230000004044 response Effects 0.000 abstract description 7
- 210000003491 skin Anatomy 0.000 description 51
- 238000011081 inoculation Methods 0.000 description 23
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940090046 jet injector Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013206520A AU2013206520B2 (en) | 2006-11-17 | 2013-06-25 | Methods of enhancing immune response using electroporation-assisted vaccination and boosting |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85972406P | 2006-11-17 | 2006-11-17 | |
| US60/859,724 | 2006-11-17 | ||
| PCT/US2007/024051 WO2008063555A2 (en) | 2006-11-17 | 2007-11-16 | Methods of enhancing immune response using electroporation-assisted vaccination and boosting |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013206520A Division AU2013206520B2 (en) | 2006-11-17 | 2013-06-25 | Methods of enhancing immune response using electroporation-assisted vaccination and boosting |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2007322075A1 AU2007322075A1 (en) | 2008-05-29 |
| AU2007322075B2 true AU2007322075B2 (en) | 2013-07-25 |
Family
ID=39430332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007322075A Active AU2007322075B2 (en) | 2006-11-17 | 2007-11-16 | Methods of enhancing immune response using electroporation-assisted vaccination and boosting |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100285040A1 (enExample) |
| EP (1) | EP2091558B1 (enExample) |
| JP (1) | JP5646851B2 (enExample) |
| KR (1) | KR20090080941A (enExample) |
| CN (1) | CN101522211A (enExample) |
| AU (1) | AU2007322075B2 (enExample) |
| CA (1) | CA2668649A1 (enExample) |
| WO (1) | WO2008063555A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010148440A1 (en) | 2009-06-24 | 2010-12-29 | International Scientific Pty Ltd | An apparatus and method of treatment utilizing a varying electromagnetic energisation profile |
| KR101723605B1 (ko) * | 2014-10-21 | 2017-04-07 | 진원생명과학 주식회사 | 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법 |
| US10233419B2 (en) | 2016-06-30 | 2019-03-19 | Zymergen Inc. | Apparatuses and methods for electroporation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040241140A1 (en) * | 2000-11-01 | 2004-12-02 | Pavlakis George N. | Expression vectors able to elicit improved immune response and methods of using same |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US118956A (en) * | 1871-09-12 | Improvement in apparatus for the manufacture of extracts from hemlock and other | ||
| US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
| US6009345A (en) | 1992-08-17 | 1999-12-28 | Genetronics, Inc. | Method and apparatus for a combination of electroporation and iontophoresis for the delivery of drugs and genes |
| US5439440A (en) | 1993-04-01 | 1995-08-08 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| US6110161A (en) | 1997-04-03 | 2000-08-29 | Electrofect As | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
| TW368420B (en) | 1997-11-04 | 1999-09-01 | Genetronics Inc | Apparatus and method for transdermal molecular delivery by applying sufficient amplitude of electric field to induce migration of molecules through pores in the stratum corneum |
| US6972013B1 (en) | 1998-07-13 | 2005-12-06 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
| EP1148885A4 (en) * | 1999-02-08 | 2002-05-08 | Chiron Corp | ELECTRICALLY INDUCED INCREASE IN IMMUNITY AND EFFECTIVENESS OF IN VIVO DNA VACCINES |
| US7171264B1 (en) * | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
| GB9922361D0 (en) * | 1999-09-21 | 1999-11-24 | Isis Innovation | Generating an immune response to an antigen |
| CA2478614C (en) | 2001-03-13 | 2013-01-15 | University Of South Florida | Electromanipulation device and method |
| WO2003072016A2 (en) * | 2001-11-19 | 2003-09-04 | Becton, Dickinson And Company | Pharmaceutical compositions in particulate form |
| EP1474153A4 (en) * | 2001-12-14 | 2005-12-14 | Genetronics Inc | PARTICLE-ASSISTED IMMUNIZATION METHODS BASED ON THE USE OF A PULSE ELECTRIC FIELD |
| US20060035853A1 (en) * | 2004-01-07 | 2006-02-16 | Biomedical Research Models, Inc. | Methods for tailoring the immune response to an antigen or immunogen |
| EP1981581B1 (en) | 2006-02-11 | 2016-04-13 | Genetronics, Inc. | Device for single-needle in vivo electroporation |
-
2007
- 2007-11-16 AU AU2007322075A patent/AU2007322075B2/en active Active
- 2007-11-16 CN CNA200780037742XA patent/CN101522211A/zh active Pending
- 2007-11-16 US US11/985,871 patent/US20100285040A1/en not_active Abandoned
- 2007-11-16 JP JP2009537218A patent/JP5646851B2/ja active Active
- 2007-11-16 KR KR1020097007135A patent/KR20090080941A/ko not_active Ceased
- 2007-11-16 EP EP07840065.2A patent/EP2091558B1/en active Active
- 2007-11-16 CA CA002668649A patent/CA2668649A1/en not_active Abandoned
- 2007-11-16 WO PCT/US2007/024051 patent/WO2008063555A2/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040241140A1 (en) * | 2000-11-01 | 2004-12-02 | Pavlakis George N. | Expression vectors able to elicit improved immune response and methods of using same |
Non-Patent Citations (2)
| Title |
|---|
| BABIUK S., et al., Electroporation improves the efficacy of DNA vaccines in large animals, Vaccine, 2002, Vol. 2, pg. 3399-3404 * |
| ZHANG L., et al., Enhancement of the effectiveness of electroporation-augmented cutaneous DNA vaccination by a particulate adjuvant, Bioelectrochemistry, 2004, Vol. 63, pg 369-373 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008063555A3 (en) | 2008-11-06 |
| EP2091558B1 (en) | 2018-04-04 |
| EP2091558A2 (en) | 2009-08-26 |
| WO2008063555A2 (en) | 2008-05-29 |
| KR20090080941A (ko) | 2009-07-27 |
| JP5646851B2 (ja) | 2014-12-24 |
| US20100285040A1 (en) | 2010-11-11 |
| CA2668649A1 (en) | 2008-05-29 |
| AU2007322075A1 (en) | 2008-05-29 |
| JP2010510218A (ja) | 2010-04-02 |
| EP2091558A4 (en) | 2012-07-04 |
| CN101522211A (zh) | 2009-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7141063B2 (ja) | 抗原およびアジュバントとしてのインターロイキン－２１を有するワクチン | |
| CN1253220C (zh) | 通过微管在真皮内输入疫苗和基因治疗剂 | |
| Luxembourg et al. | Electroporation-based DNA immunisation: translation to the clinic | |
| Kisakov et al. | The use of electroporation to deliver DNA-based vaccines | |
| JP7011241B2 (ja) | Ｗｔ１ワクチン | |
| CN104168912B (zh) | 促进剂-dna组合疫苗 | |
| WO2001085202A2 (en) | Electroporation for introduction of molecules into cells | |
| US20210353939A1 (en) | Multiple Tissue Layer Electroporation Applicator and Device | |
| MX2011012807A (es) | Composiciones y metodos para administracion de vacunas contra virus del dengue. | |
| Dobaño et al. | Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation | |
| US20130005028A1 (en) | Activation of RIG-I Pathway | |
| AU2007322075B2 (en) | Methods of enhancing immune response using electroporation-assisted vaccination and boosting | |
| AU2013206520B2 (en) | Methods of enhancing immune response using electroporation-assisted vaccination and boosting | |
| US11179458B2 (en) | Immunogenicity of an optimized synthetic consensus DNA vaccine for porcine epidemic diarrhea virus | |
| HK1135848A (en) | Methods of enhancing immune response using electroporation-assisted vaccination and boosting | |
| IL302645A (en) | Dna encoded nanoparticles and method of use thereof as a coronavirus disease 2019 (covid-19) vaccine | |
| US20250255954A1 (en) | Stabilized spike protein and method of use thereof as a coronavirus disease 2019 (covid-19) vaccine | |
| WO2024182700A2 (en) | Glycan modified sars-cov-2 glycoprotein nanoparticles and methods of use thereof | |
| US20230321230A1 (en) | Compositions and Methods for Adjuvanted Vaccines | |
| WO2025038695A1 (en) | Modified h3 hemagglutinin antigens and methods of use thereof | |
| US20190307704A1 (en) | Method for enhanced delivery of gene based therapy and vaccination using electroporation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |